Abstract: One of the most common risks after a heart transplant is bleeding. In this study, the effect of desmopressin administration on the amount of bleeding and transfusion requirements after heart transplant surgery was investigated. In a double-blind clinical trial, 48 patients who were candidates for heart transplant surgery were randomly assigned to two groups. In the intervention group, patients received desmopressin of 0.3 lg/kg, 30 min. before surgery. Patients in the control group received normal saline at the same amount and time. Homeostasis was evaluated using activated clotting time (ACT), PT, PTT and PLT before, 12 and 24 hr after surgery, and also, chest tube drainage, blood products transfusion requirements during the first day in both groups. No significant differences were found between the groups in terms of ACT, PT, PTT and PLT at all times. Transfusion of packed red blood cells and the mean drainages of chest tube during the first 24 hr after surgery were significantly lower in the desmopressin group compared to the saline group. Desmopressin may reduce post-operative bleeding in patients undergoing heart transplant surgery. Further studies are required to confirm the potential effect of desmopressin on establishing haemostasis after heart transplantation.
Heart transplantation is a widely accepted treatment option for patients with end-stage congestive heart failure (NYHA class III or IV) despite advanced medical and resynchronization therapy [1, 2] . Other indications for heart transplantation include refractory cardiogenic shock requiring continuous intravenous inotropic therapy or haemodynamic support devices, refractory disabling angina, recurrent life-threatening left ventricular arrhythmias despite an implantable cardioverter defibrillator, anti-arrhythmic medications or catheter-based ablation [1] [2] [3] [4] . Approximately 4000 heart transplants are performed annually worldwide with 12-year post-transplant survival rate of 50% [4, 5] .
Heart transplant is a major procedure which requires open heart surgery and cardiopulmonary bypass (CPB) [6, 7] . Cardiopulmonary bypass is associated with early post-operative complications including vasoplegic syndrome, altered platelet responses, haematologic disorders, myocardial infarction and neurological and renal impairment [8] [9] [10] [11] .
Bleeding is one of the common complications immediately after heart transplant surgery. In 10% of patients undergoing CPB, severe bleeding requiring large-volume transfusion of blood (packed red blood cells) occurs [12] . Heavy bleeding is caused by several different factors such as inadequate haemostasis, remaining heparin effects after CPB, reduction in coagulation factors, hypothermia, diluted blood (coagulopathy and thrombocytopenia dilution), platelet disorders, as well as drainage from incision sites [12, 13] . In addition, patients suffering from end-stage heart failure frequently develop liver dysfunction due to chronic hepatic venous congestion, which is associated with coagulation disorders and prolonged PT [14] .
In order to reduce the amount of bleeding during cardiac surgery, medications such as Ɛ-aminocaproic acid (Amicar) and tranexamic acid, aprotinin and erythropoietin are recommended [15] [16] [17] [18] . Some of the complications reported for aprotinin include anaphylaxis, renal failure, arterial thrombosis and increased risk of mortality [15] . Tranexamic acid potentially increases risk of generalized seizures and perioperative myocardial infarction [19] , and the most serious side effects of erythropoietin are increased systolic pressure and thrombotic events [20] .
Desmopressin (1-deamino-8-D-arginine vasopressin DDAVP) is a synthetic analogue of vasopressin, an antidiuretic hormone, which was first used for the prevention and treatment of bleeding after tooth extractions and then to reduce amount of bleeding and transfusion requirements during major surgery [21] . Currently, this drug is used for the management of haemorrhage in patients with mild haemophilia A and type 1 von Willebrand diseases (VWD) [22, 23] . In 1986, desmopressin was introduced as an alternative to blood transfusion for patients undergoing heart surgery [24] . Unlike vasopressin hormone, desmopressin creates less vasoconstriction resulting only in a minor increase in blood pressure, and it does not increase gut and uterine motility and can be well tolerated by patients [25] . Desmopressin shortens PTT and bleeding time (BT) although increased amounts of factor VIII and von Willebrand factor (vWF) are involved in the intrinsic pathway of coagulation and haemostasis [26] . Desmopressin has no effect on the platelet number or aggregation; however, it strengthens the platelet adhesion to the vessel wall [27] . Complications reported for desmopressin include mild facial flushing, headache, palpitations and hypotension [28] . Thrombotic complications including myocardial infarction, stroke, arterial thrombosis and venous thromboembolism are also rarely seen [29] . Medical effects of desmopressin in reducing blood loss during and after major surgeries have been shown, while the amount of bleeding after intravenous administration of desmopressin in patients undergoing heart transplantation has not been studied. Therefore, this study was carried out to investigate the effectiveness of desmopressin on the amount of bleeding and transfusion requirements in patients undergoing heart transplant surgery.
Patients and Methods
In a double-blind, randomized, clinical trial, patients who were scheduled to undergo heart transplantation in Masih Daneshvari Hospital, Tehran, Iran, from February 2014 to May 2016, were randomly selected. This study was approved by the Ethics Committee of the Shaheed Beheshti University of Medical Sciences. All recruited patients provided informed and written consent to the study. Exclusion criteria included 20< age >70 years, history of previous surgery on the chest, bleeding haemophilia problems, patients with pre-operative platelet coagulation disorders, any problem where desmopressin is contraindicated, history of deep vein thrombosis, haematologic disease, carotid plaque that leads to obvious and chronic obstructive pulmonary disease. Taking into account the quantitative conditions of sample size with first type error (a) at 0.05 level and second type error (b) at 0.020 level (power 80%), the number of sample for each group was considered to be 24. Therefore, 48 patients were included in the study and they were randomly assigned into two groups. Patients were assigned into two groups using randomized method and table of randomized numbers.
The intervention group received 0.3 lg/kg desmopressin so that its volume reached to 50 cc within 10 min., and patients in the control group received 50 cc normal saline. In both groups, injection was intravenously given 30 min. before surgery. Syringes containing drugs or placebo were prepared by one of the nursing staff outside the operating room and they were delivered to the operating room personnel. Surgeon, anaesthesiologist, assistant, scrub nurse and one who was in charge of cardiopulmonary pump were unaware of the contents of the syringes.
All patients were premedicated with clonazepam of 2 mg at maximum (0.03 mg/kg) and morphine of 0.15 k/gm intramuscularly 30 min. before surgery. Anaesthesia was induced by sufentanil of 2 mg/kg, thiopental of 3 mg/kg and pancuronium of 0.1 mg/kg and was maintained with isoflurane of 0.5-1%, and during CPB, it was maintained with atracurium 01/mg1kg/hw and fentanyl 1-2 gm/gk and midazolam 0.5-1 gm/gk. All patients received heparin 300 IU/kg before CPB to achieve an activated clotting time (ACT) of more than 480 sec. During CPB, to achieve the target ACT, additional heparin was prescribed, and after the separation from CPB and heparin neutralization, protamine sulphate (1 mg per 100 units of heparin) was prescribed to reach the targeted ACT level (80-120 sec.).
Patients were monitored in the intensive care unit (ICU). Chest tube drainages were measured at 6, 12 and 24 hr after surgery. The chest tube was removed if the drainage was <80-100 during 12-hr period. Blood and blood products were transfused based on blood transfusion strategy. Additionally, haemoglobin and haematocrit levels before, 6, 12 and 24 hr after surgery were measured. Also, transfusion requirements of packed red blood cells, fresh frozen plasma (FFP), platelets and cryoprecipitate within the first 24 hr, coagulation laboratory tests including PT, INR, PTT, ACT and platelets before, 12 and 24 hr after surgery and mandatory reoperation due to bleeding during the first 48 hr of the surgery were investigated. Additionally, age, gender, body mass index (BMI), underlying diseases, operating time, CPB length, receiving intraoperative colloids (albumin, gluten, colloids and Voluven), intravenous inotropic therapy (dopamine, dobutamine, norepinephrine and epinephrine), inotrope score, urinary output in the operating room and first 24 hr after surgery, duration of mechanical ventilation, length of hospitalization in ICU and potential thrombotic events such as myocardial infarction and stroke were recorded using a questionnaire. The occurrence of myocardial infarction was defined on the basis of increased cardiac enzyme concentration and results of electrocardiography. Also, brain imaging was used to diagnose the stroke.
The data obtained were entered in SPSS (Statistical Package for Social Sciences for Windows, version 22.0; SPSS Inc., Chicago, IL, USA). Statistical analysis was performed by Kolmogorov-Smirnov, chisquare, Fisher's exact, Mann-Whitney and Student's t-tests where appropriate. The level of statistical significance was set at p value <0.05.
Results
A total of 48 patients were evaluated with mean age of 47 AE 11.5. Of them, 15 (31.25%) were men and 33 patients (68.75%) were women. Table 1 shows patients' demographic, surgery and hospitalization information for both groups. The most frequent underlying diseases in both groups were renal failure (32%, n = 9), followed by diabetes (32%, n = 9). There were no significant differences between the two groups in terms of age, gender, BMI, haemoglobin and haematocrit, underlying diseases, operation time, CPB length, mechanical The mean chest tube drainage at 24 hr in the desmopressin group was 411 AE 48 mL, while it was 495 AE 65 mL in the control group, which was significantly different (p = 0.037). Packed red blood cells were the only blood product, which was significantly less frequently transfused in the desmopressin group compared to the control group (2 AE 0.7 U versus 4.2 AE 0.9, p = 0.41). Urine output was not significantly different in the operating room and 24 hr after surgery between the groups. Table 2 shows chest tube drainage, transfusion requirements and urine output.
Data analysis showed that ACT, PT, PTT and INR, PLT before and after surgery were not significantly different between the groups. In addition, ACT was normal at all times. Table 3 shows detailed information about the coagulation laboratory tests.
Discussion
No study has been conducted to investigate the effectiveness of desmopressin on the amount of bleeding during heart transplant surgery, and this clinical trial is the first study in this regard. A potential early complication of heart transplantation is bleeding, which is associated with increased mortality. Our finding suggests that 0.3 lg/kg desmopressin administration in patients undergoing heart transplant may be appropriate in reducing the chest tube drainages and need for packed red blood cells transfusion, without changes in coagulation functions during and after surgery.
Most studies on the haemostatic effects of desmopressin have been conducted in the late 1980s and early 1990s. The variables assessed in these studies to evaluate the effects of desmopressin mostly include the amount of bleeding loss during and after surgery, need for packed red blood cells, FFP and platelet transfusions, factors VIII and vWF, BT, mandatory reoperation due to bleeding [27, 30, 31] . A few studies have also been conducted to examine the status of coagulation (using tests such as clot ratio, ristocetin cofactor and platelet aggregation time), haemodynamics by measuring systemic vascular resistance, myocardial infarction during and after surgery and mortality rate. In a study conducted by Salzman et al. on 70 patients who underwent cardiac surgery (valve replacement and CABG), desmopressin or placebo was given for patients after reversing heparin with protamine. In the group treated with desmopressin, reduced amount of bleeding during and 24 hr after surgery and reduced packed red blood cells transfusion requirement were observed. In addition, patients who had lower factor VIII/vWF before surgery were more likely to present with bleedings [24] . The results of this study are similar to our study, while factor VIII/vWF was not considered in our study. Czer et al. [32] showed less need for packed red blood cells and platelets transfusions, shortened BT and increased factors VIII and vWF after desmopressin administration in cardiac surgery patients.
In an RCT study on 100 patients with valve replacement, Rocha et al. found that the intraoperative bleeding was lower in the desmopressin group compared to the control group, but the volume of post-operative bleeding and transfusion requirements was not significantly different between the groups. The level of factors VIII and vWF increased significantly, and BT shortened at 24 hr after surgery [33] . However, in several studies carried out in patients undergoing coronary artery bypass graft (CABG), significant differences were not observed between the desmopressin group and placebo group in reducing bleeding and transfusion requirements [32] [33] [34] [35] [36] .
In a study conducted by Gratz et al. in 15 patients who underwent CABG and required CPB, a significant reduction in amount of bleeding during and after surgery was seen in the desmopressin group compared to the placebo group. There was no difference in the transfusion needs, while need for platelets transfusion decreased. In addition, factor VIII: C significantly increased 90 min. after injection of desmopressin. Dilthey et al. did not find significant difference in the volume of bleeding, but they found a significant reduction in the transfusion requirements and a significant increase in vWF 4 hr after desmopressin infusion [37] . In another study by Reynolds et al. [38] in 95 children who underwent simple and complex cardiac surgery, there was no difference between the desmopressin and placebo groups in terms of reducing bleeding 24 hr after surgery, transfusion requirements and coagulation factors.
Moreover, Ozkisacik et al. [39] investigated the effect of desmopressin on the amount of bleeding after CABG surgery where no effect was seen on post-operative haemostasis in patients undergoing elective surgery without bleeding disorders. In a meta-analysis study, Crescenzi et al. reviewed 38 randomized clinical trial studies. They found that injection of 0.3 lg/kg desmopressin reduced almost 80 cc of bleeding and 0.3 U packed red blood cells transfusion per patient, without changes in coagulation functions. However, this effect was more pronounced in patients undergoing non-cardiac surgery [40] . Cattaaneo recommended the use of desmopressin in patients undergoing cardiac surgery with bleeding problems such as haemophilia. However, to conclude the effect of desmopressin in this study, a randomized clinical trial is needed [41] .
In our study, ACT was used to investigate the coagulation status, which was in the normal range at 12 and 24 hr after the surgery. In this regard, Jin and Ji examined PLT aggregation through ristocetin, arachidonic acid and adenosine diphosphate as aggregation agents before surgery, during 0.3 lg/kg desmopressin injection and 2 hr after injection in patients with valve replacement surgery. Results showed no significant difference between the two groups desmopressin and control. In addition, no significant difference was found between the two groups in terms of mechanical ventilation duration, cardiovascular side effects and ICU hospitalization [27] .
Myocardial infarction is a rare but serious side effect in patients receiving desmopressin. In our study, use of desmopressin was not associated with myocardial infarction. Levi et al. [42] found a 2.4-fold increase in the incidence of myocardial infarction in the desmopressin group compared with the placebo group. However, Crescenzi et al. [40] did not substantiate an increased risk of myocardial infarction in cardiac surgery (4.3% in the desmopressin group versus 3.1% in the placebo group). Carless et al. also reviewed 12 trials that included a total of 876 patients, of whom 441 were randomized to desmopressin. In their study, the rate of myocardial infarction was 6.35% (28 patients) in the desmopressin group and 4.14% (18 patients) in the control group, and the result failed to reach statistical significance [43] . Therefore, because it appeared that thrombotic events tend to be more frequent in desmopressin-treated patients, it should be used with caution in elderly patients with atherosclerotic disease.
Desmopressin has a 60% higher affinity than antidiuretic hormone for the V2 receptor, so it may be associated with fluid retention [44] . In this study, we recorded urine output in the operation room and the first 24 hr after surgery, and the results showed no significant difference in the patients' urine output between both groups. According to the results of prior studies conducted on patients undergoing cardiac surgery, antidiuretic effect of desmopressin is minor and hyponatraemia is more likely to occur with repetitive dosing [27, 45, 46] . This may be due to careful monitoring and attention to fluid intake and prevention of fluid overload with advanced bedside devices. In addition, hyponatraemia and fluid retention are more likely to occur in young children with multiple desmopressin doses or with aggressive fluid replacement during surgery [27, 46] .
Limitations
One limitation of our study was the lack of investigating coagulation factors. Therefore, further studies are required in this regard to seek coagulation factors accompanied by clinical hepatic and cardiac examinations. The strengths of our study were random selection and allocation of patients into groups and also controlling the placebo effect.
Conclusion
Intravenous administration of desmopressin may be an effective and safe approach to reduce post-operative bleeding and packed red blood cells in patients undergoing heart transplant surgery. However, further studies are required to confirm potential effect of desmopressin on the establishment of haemostasis after heart transplantation. 
